WO2018016783A1 - Composition hydratante contenant du 3-o-galloyl-3,3',5,5',7-pentahydroxyflavane - Google Patents

Composition hydratante contenant du 3-o-galloyl-3,3',5,5',7-pentahydroxyflavane Download PDF

Info

Publication number
WO2018016783A1
WO2018016783A1 PCT/KR2017/007294 KR2017007294W WO2018016783A1 WO 2018016783 A1 WO2018016783 A1 WO 2018016783A1 KR 2017007294 W KR2017007294 W KR 2017007294W WO 2018016783 A1 WO2018016783 A1 WO 2018016783A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition
weight
galloyl
acid
pentahydroxyflavan
Prior art date
Application number
PCT/KR2017/007294
Other languages
English (en)
Korean (ko)
Inventor
홍용덕
최민식
조시영
김정기
Original Assignee
(주)아모레퍼시픽
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by (주)아모레퍼시픽 filed Critical (주)아모레퍼시픽
Priority to JP2018526252A priority Critical patent/JP7030692B2/ja
Priority to CN201780013667.7A priority patent/CN108697143B/zh
Publication of WO2018016783A1 publication Critical patent/WO2018016783A1/fr
Priority to HK18113766.5A priority patent/HK1254516A1/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
    • A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9789—Magnoliopsida [dicotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/318—Foods, ingredients or supplements having a functional effect on health having an effect on skin health and hair or coat
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2300/00—Processes
    • A23V2300/18—Fractionation

Definitions

  • This specification includes 3-O-galloyl-3,3 ', 5,5', 7-pentahydroxyflavan (3-O-galloyl -3,3 ', 5,5', 7-pentahydroxyflavan) It relates to a composition for moisturizing.
  • Human skin acts as a barrier to protect individuals from the outside.
  • the barrier function is to protect against various stimuli (chemicals, air pollutants, dry environment, ultraviolet rays, etc.) from the outside and to prevent excessive release of moisture through the skin, and this protection function is a stratum corneum composed of keratinocytes.
  • This protection function is a stratum corneum composed of keratinocytes.
  • the function can be maintained only when is normally formed.
  • the outermost stratum corneum (horney layer) of the epidermis is formed from keratinocytes and consists of complete differentiated keratinocytes and the surrounding lipid layer (Marcelo CL et al, J. Invest. Dermatol., 80, pp 37-44, 1983).
  • keratinocytes form a natural moisturizing factor (NMF) and intercellular fats (ceramides, cholesterol, fatty acids), forming a stratum corneum, making the stratum corneum firm and flexible, making it a skin barrier. It serves as a function.
  • NMF natural moisturizing factor
  • ceramides, cholesterol, fatty acids intercellular fats
  • the stratum corneum can easily lose its function due to excessive face washing, lifestyle factors such as bathing, environmental factors such as dry air pollutants, and endogenous diseases such as atopic or aged skin. Recently, due to a variety of factors, more and more cases of dry skin symptoms and related complaints are increasing.
  • the present invention relates to a moisturizing substance derived from natural products in one aspect, and to provide a moisturizing composition comprising a post-fermented tea fraction accordingly.
  • the present invention provides 3-O-galloyl-3,3 ', 5,5', 7-pentahydroxyflavane (3-O-galloyl-3,3 ', isolated from post-fermented tea fractions.
  • An object of the present invention is to provide a moisturizing composition comprising 5,5 ', 7-pentahydroxyflavan) as an active ingredient.
  • 3-O-galloyl-3,3 ', 5,5', 7-pentahydroxyflavane (3-O-galloyl-3,3 ', 5 , 5 ', 7-pentahydroxyflavan), an isomer thereof, an acceptable salt thereof, a prodrug thereof, a hydrate thereof, a solvate thereof, or a post-fermented tea ketone fraction comprising the same as an active ingredient.
  • the present invention provides 3-O-galloyl-3,3 ', 5,5', 7-pentahydroxyflavane (3-O-galloyl-3,3 ', 5,5', 7- pentahydroxyflavan), an isomer thereof, an acceptable salt thereof, a prodrug thereof, a hydrate thereof, a solvate thereof, or a post-fermented tea ketone fraction comprising the same, is provided to the individual as an active ingredient.
  • the present invention provides 3-O-galloyl-3,3 ', 5,5', 7-pentahydroxyflavane (3-O-galloyl-3) for use in preparing a skin moisturizing composition. , 3 ', 5,5', 7-pentahydroxyflavan), an isomer thereof, an acceptable salt thereof, a prodrug thereof, a hydrate thereof, a solvate thereof, or a post-fermented tea ketone fraction comprising the same.
  • 3-O-galloyl-3,3 ', 5,5', 7-pentahydroxyflavane (3-O-galloyl-3,3 'as an active ingredient for skin moisturizing , 5,5 ', 7-pentahydroxyflavan), an isomer thereof, an acceptable salt thereof, a prodrug thereof, a hydrate thereof, a solvate thereof, or a post-fermented tea ketone fraction comprising the same.
  • 3-O-galloyl-3,3 ', 5,5', 7-pentahydroxyflavane (3-O-galloyl-3,3 as an active ingredient for skin moisturizing ', 5,5', 7-pentahydroxyflavan), an isomer thereof, an acceptable salt thereof, a prodrug thereof, a hydrate thereof, a solvate thereof, or a post-fermented tea ketone fraction comprising the same.
  • the present invention provides a composition comprising a post-fermented tea ketone fraction and a composition comprising a specific compound, it can be widely used in the field of moisturizing.
  • Figure 1 shows the results of analyzing the fermented tea extract by high performance liquid chromatography, and shows the case of passing through and without the acetone fraction.
  • Figure 2 shows the caffeine-free chloroform: methanol 10: 1 (v / v) fraction divided into 10 sub-fractions using high-performance countercurrent chromatography (HPCCC).
  • HPCCC high-performance countercurrent chromatography
  • Figure 3 shows for fractions 1 to 5 of the ten subfractions fractionated using HPCCC.
  • Figure 4 shows for fractions 6 to 10 of the 10 subfractions fractionated using HPCCC.
  • NMR nuclear magnetic resonance
  • post-fermented tea includes fermented by a separate microorganism or substance other than the enzyme present in the tea leaf.
  • the "ketone fraction” includes the fractionation of a specific substance or extract using a ketone solvent or the fraction remaining, and the extraction of these with a specific solvent again.
  • Acetone is preferred although the type of ketone is any, and the fractionation method and extraction method may be any method known to those skilled in the art.
  • isomers in particular are not only optical isomers (eg, essentially pure enantiomers, essentially pure diastereomers or mixtures thereof), but also form isomers ( conformation isomers (ie, isomers that differ only by their angles of one or more chemical bonds), position isomers (especially tautomers) or geometric isomers (eg, cis-trans isomers) do.
  • essentially pure means at least about 90%, preferably at least about 95%, of a specific compound, for example enantiomers or diastereomers, when used in connection with an enantiomer or diastereomer. More preferably at least about 97% or at least about 98%, even more preferably at least about 99%, even more preferably at least about 99.5% (w / w).
  • “acceptable” means that it can be approved or approved by the government or equivalent regulatory body for use in animals, more specifically in humans, by avoiding significant toxic effects when used in conventional or pharmaceutical dosages. Recognized or enumerated as listed in the Food Code, Health Functional Food Code, or General Pharmacopoeia or as described in other general literature.
  • acceptable salt means a salt according to one aspect of the invention, either conventional or pharmaceutically acceptable and having the desired activity of the parent compound.
  • the salt is formed from (1) an inorganic acid such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, or the like; Or acetic acid, propionic acid, hexanoic acid, cyclopentanepropionic acid, glycolic acid, pyruvic acid, lactic acid, malonic acid, succinic acid, malic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, 3- (4-hydroxybenzoyl) Benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, 1,2-ethane-disulfonic acid, 2-hydroxyethanesulfonic acid, benzenesulfonic acid, 4-chlorobenzenesulfonic acid,
  • prodrug refers to a drug that modulates physical and chemical properties by chemically changing a substance, and itself does not exhibit physiological activity, but the action of chemical, physiological or enzymes in the body after administration. By changing to the original drug can take effect.
  • hydrate refers to a compound to which water is bound, and is a broad concept including an inclusion compound having no chemical bonding force between water and the compound.
  • solvate means a higher order compound produced between molecules or ions of a solute and molecules or ions of a solvent.
  • 3-O-galloyl-3,3 ', 5,5', 7-pentahydroxyflavane (3-O-galloyl-3,3 ', 5, 5 ', 7-pentahydroxyflavan), an isomer thereof, an acceptable salt thereof, a pharmaceutically acceptable salt thereof, a prodrug thereof, a hydrate thereof, a solvate thereof, or a post-fermented tea ketone fraction comprising the same as an active ingredient.
  • the moisturizing includes skin moisturizing.
  • the post-fermented tea ketone fraction may be a ketone fraction for the water-insoluble extract of the post-fermented tea.
  • the 3-O-galloyl-3,3 ', 5,5', 7-pentahydroxyflavane is trans-3-O-galloyl-3,3 'represented by Formula 2 below.
  • 5,5 ', 7-pentahydroxyflavan Trans-3-O-galloyl-3,3', 5,5 ', 7-pentahydroxyflavan.
  • “Flavan” in this specification refers to the 3-O-galloyl-3,3 ', 5,5', 7-pentahydroxyflavan or trans-3-O-galloyl-3,3 ', 5,5 ', 7-pentahydroxyflavane is shown.
  • the ketone fraction may be an alcohol extract of the ketone fraction.
  • the ketone is acetone, carvon, pulegone, isolongifolanone, 2-heptanone, 2-pentanone, 3-hexanone, 3-heptanone , 4-heptanone, 2-octanone, 3-octanone, 2-nonanone, 3-nonanone, 2-undecanone, 2-tridecanone, methyl isopropyl ketone, ethyl isoamyl ketone, butyl Dencetone, methylheptenone, dimethyloctenone, geranyl acetone, farnesyl acetone, 2,3-pentadione, 2,3-hexadione, 3,4-hexadione, 2,3-heptadione, amylcyclopenta Paddy, amylcyclopentenone, 2-cyclopentyl cyclopentanone, hexylcyclopentanone, 2-n-heptylcyclopentanone,
  • the alcohol may be an alcohol alone or a mixture which can be generally used in the art, preferably ethanol.
  • 3-O-galloyl-3,3 ', 5,5', 7-pentahydroxyflavane or trans-3-O-galloyl-3,3 ', 5, 5 ', 7-pentahydroxyflavan, isomer thereof, acceptable salt thereof, pharmaceutically acceptable salt thereof, prodrug, hydrate thereof, or solvate thereof is at least 0.000001% by weight, 0.000005, based on the total weight of the composition Or more, 0.00001 or more, 0.00005 or more, 0.0001 or more, 0.0002 or more, 0.0005 or more, 0.001 or more, 0.001 or more, 0.005 or more, 0.01 or more, 0.05 or more, 0.1 or more More than 0.3%, More than 0.3%, More than 0.5%, More than 1%, More than 1.5%, More than 1.8%, More than 2%, More than 2.2%, More than 2.5%, More than 2.8%, 3 At least 3.2 wt%, at least 3.5 wt%, at least 3.8 w
  • the content of the post-fermented tea ketone fraction in the composition is 0.01% by weight, 0.1% by weight, 1% by weight, 5% by weight, 10% by weight, 15% by weight relative to the total weight of the composition. 20% by weight, 25% by weight, 30% by weight, 35% by weight, 40% by weight, 45% by weight, 50% by weight, 55% by weight, 60% by weight, 65% by weight Or more, 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 100% or less, 95% or less, 90% or less, 85 Up to 80% by weight, up to 75% by weight, up to 70% by weight, up to 65% by weight, up to 60% by weight, up to 55% by weight, up to 50% by weight, up to 45% by weight, up to 40% by weight, 35 Up to 30% by weight, up to 25% by weight, up to 20% by weight, up to 15% by weight, up to 10% by weight, up to 5% by weight, up to 1% by weight, up to 0.1%
  • the fraction is 3-O-galloyl-3,3 ', 5,5', 7-pentahydroxyflavan or trans-3-O-galloyl-3,3 ', 5, 5 ', 7-pentahydroxyflavan, an isomer thereof, an acceptable salt thereof, a pharmaceutically acceptable salt thereof, a prodrug, a hydrate thereof, or a solvate thereof is at least 0.0001% by weight, 0.0002, based on the total weight of the fraction At least 0.0005 wt%, at least 0.001 wt%, at least 0.005 wt%, at least 0.01 wt%, at least 0.05 wt%, at least 0.1 wt%, at least 0.5 wt%, at least 1 wt%, at least 1.5 wt%, 2 wt% At least 2.5%, at least 3%, at least 3.5%, at least 4%, or at least 4.5%, at most 5%, at most 4.5%, at most 4%, at most
  • the dosage of, 7-pentahydroxyflavane, isomer thereof, acceptable salt thereof, pharmaceutically acceptable salt thereof, prodrug thereof, hydrate thereof, or solvate thereof is at least 0.0001 g / kg / day, 0.001 g / kg / day or more, 0.01g / kg / day or more, 0.1g / kg / day or more, 1g / kg / day or more, 2g / kg / day or more, 3g / kg / day or more, 4g / kg / day or more, 5g / kg / day or more, 6g / kg / day or more, 7g / kg / day or more, 8g / kg / day or more, 9g / kg / day or more, 10g / kg / day
  • the moisturizing may be due to any one or more of increased water supply and prevention of water loss.
  • the composition according to one aspect of the invention may be a pharmaceutical composition.
  • the pharmaceutical composition may be administered orally, parenterally, rectally, topically, transdermally, intravenously, intramuscularly, intraperitoneally, subcutaneously.
  • Formulations for oral administration may be tablets, pills, soft and hard capsules, granules, powders, granules, solutions, emulsions or pellets, but are not limited thereto. It is not.
  • Formulations for parenteral administration may be, but are not limited to, solutions, suspensions, emulsions, gels, injections, drops, suppositories, patches, ointments or sprays.
  • the formulations can be readily prepared according to conventional methods in the art and include surfactants, excipients, hydrating agents, emulsifiers, suspending agents, salts or buffers for controlling osmotic pressure, colorants, spices, stabilizers, preservatives, preservatives or Other commercially available auxiliaries may further be included.
  • the dosage or dosage of the composition according to one aspect of the invention will vary depending on the age, sex, weight, pathology and severity of the subject to be administered, the route of administration or the judgment of the prescriber. Application dose determination based on these factors is within the level of one skilled in the art and the daily dose of the active ingredient is for example 0.001 ⁇ g / kg / day to 5000 mg / kg / day, more specifically 0.0001 mg / kg / day to 15 mg / kg / day, but is not limited thereto.
  • the composition may be a food composition or a health food composition.
  • the formulation of the food composition or health food composition is not particularly limited, but may be, for example, formulated into a liquid such as tablets, granules, pills, powders, capsules, drinks, caramels, gels, bars, tea bags, and the like.
  • the food composition or health food composition of each formulation can be appropriately selected and formulated by those skilled in the art according to the formulation or purpose of use, in addition to the active ingredients, depending on the formulation or purpose of use, and synergistic effect when applied simultaneously with other raw materials Can happen.
  • composition may be administered by various methods such as simple ingestion, drinking, injection administration, spray administration or squeeze administration.
  • the dosage determination of the active ingredient is within the level of those skilled in the art, the daily dosage of which is, for example, 0.0001 mg / kg / day to 15 mg / kg It may be / day, but is not limited thereto, and may vary depending on various factors such as age, health condition, and complications of the subject to be administered.
  • Food composition or health food composition for example, a variety of food products such as chewing gum, caramel products, candy, ice cream, confectionery, beverage products such as soft drinks, mineral water, alcoholic beverages, vitamins and minerals Health functional food, including the like.
  • the food composition or health food composition according to an aspect of the present invention is a variety of nutrients, vitamins, minerals (electrolytes), synthetic flavors and natural flavoring agents, such as colorants and enhancers (cheese, chocolate, etc.), Pectic acid and salts thereof, alginic acid and salts thereof, organic acids, protective colloidal thickeners, pH adjusting agents, stabilizers, preservatives, glycerin, alcohols, carbonation agents used in carbonated beverages and the like.
  • the food compositions according to one aspect of the present invention may include a pulp for producing natural fruit juice and fruit juice beverage and vegetable beverage. These components can be used independently or in combination. The proportion of such additives is not so critical but is typically included in the range of 0 to about 50 parts by weight per 100 parts by weight of the composition according to one aspect of the invention.
  • the composition may be a topical skin composition.
  • the external preparation composition for skin may be a composition such as cosmetics, mouthwash, cleaning agent, medicine and pharmaceuticals, but is not limited thereto.
  • the external preparation for the skin is not particularly limited in the formulation, for example, supple cosmetics, astringent cosmetics, nourishing cosmetics, nutrition cream, massage cream, essence, eye cream, eye essence, cleansing cream, cleansing foam, cleansing water, It can be formulated into cosmetics such as packs, powders, body lotions, body creams, body oils and body essences.
  • the topical skin composition of the present disclosure may further include at least one selected from functional salts for a particular purpose and a pH adjusting agent for adjusting pH.
  • the salt may be selected from inorganic salts, organic salts and / or organic-inorganic salts for ion shielding, moisturizing, UV protection, and the like.
  • the salt may be selected from sodium chloride (NaCl), sodium phosphate (Na 3 PO 4), calcium chloride (CaCl 2), and the like.
  • the pH adjuster is selected from acids and bases, for example hydrochloric acid, sulfuric acid, tartaric acid, citric acid, phosphoric acid, acetic acid, lactic acid, sodium lactate, sodium hydroxide, potassium hydroxide, alkyl amines, alkanes It may be selected from the group consisting of olamine, ammonia and the like.
  • the external preparation composition for skin herein may be a cosmetic, pharmaceutical or quasi-drug composition.
  • the cosmetic, pharmaceutical or quasi-drug composition may further contain preservatives, stabilizers, hydrating or emulsifying accelerators, auxiliaries such as salts and / or buffers for osmotic pressure control and other therapeutically valuable substances.
  • the composition may be formulated into a lotion, cream, ointment or gel and the like. It is preferable that the said external preparation composition for skin is administered transdermally.
  • the dosage of the active ingredient of the pharmaceutical or quasi-drug composition will vary depending on the age, sex and weight of the subject to be treated, the specific disease or pathological condition to be treated, the severity of the disease or pathological condition, the route of administration and the judgment of the prescriber. Dosage determination based on these factors is within the level of skill in the art. In general, the dosage of the active ingredient may range from 0.0001 mg / kg / day to 15 mg / kg / day, but is not limited thereto.
  • the composition is not particularly limited in formulating, but may be a cosmetic composition.
  • the cosmetic composition is, for example, a skin and / or hair composition, for example, supple cosmetics, astringent cosmetics, nourishing cosmetics, nutrition cream, massage cream, eye cream, eye essence, essence, cleansing cream, cleansing lotion, cleansing foam, Cleansing water, packs, powders, body lotions, body creams, body essences, body cleaners, hair dyes, shampoos, rinses, hair styling agents, wool, ointments, gels, creams, patches, sprays and skin adhesives. It is not limited to this.
  • composition according to the present specification may be a cosmetic composition, and the cosmetic composition may be provided in any formulation suitable for topical application.
  • the cosmetic composition may be provided in the form of a solution, an emulsion obtained by dispersing an oil phase in an aqueous phase, an emulsion obtained by dispersing an aqueous phase in an oil phase, a suspension, a solid, a gel, a powder, a paste, a microneedle, a foam, or an aerosol composition.
  • Compositions of such formulations may be prepared according to conventional methods in the art.
  • the cosmetic composition according to the present specification may further include functional additives and components included in general cosmetic compositions in addition to the compounds or fractions herein.
  • the functional additive may include a component selected from the group consisting of water-soluble vitamins, oil-soluble vitamins, polymer peptides, polymer polysaccharides, sphingolipids and seaweed extract.
  • the cosmetic composition according to the present specification may include other ingredients that may give a synergistic effect to the main effect, preferably within a range that does not impair the main effect.
  • the cosmetic composition according to the present specification may further include a moisturizer, an emulsifier, a surfactant, a ultraviolet absorbent, a preservative, a bactericide, an antioxidant, a pH adjuster, an organic and an inorganic pigment, a perfume, a cooling agent, or a restricting agent.
  • a moisturizer an emulsifier, a surfactant, a ultraviolet absorbent, a preservative, a bactericide, an antioxidant, a pH adjuster, an organic and an inorganic pigment, a perfume, a cooling agent, or a restricting agent.
  • the blending amount of the above components can be easily selected by those skilled in the art within the range that does not impair the purpose and effect of the present specification, the blending amount may be 0.001 to 10% by weight, specifically 0.01 to 3% by weight based on the total weight of the composition. have.
  • the water content was adjusted to 40 wt% by adding water to the green tea made from green tea ( Camellia sinensis var. Yabukita ) leaves.
  • Bacillus subtillis Bacillus subtillis 5 ⁇ 10 6 cfu / g was inoculated, fermented for 3 days at 50 °C and then fermented at 80 °C 4 days.
  • the fermented tea was dried to 4 to 6% by weight of water with hot air of 70 ° C to 80 ° C, and then aged at 10 ° C for 100 days.
  • the aged tea sample was ground for 15 seconds and filtered through a stainless steel sieve of mesh size 1 mm. Thereafter, the pulverized 50mg was added to 1.5ml Eppendorf tube, 1ml of deionized water was added, stirred at a constant speed for 30 minutes in a 60 ° C constant temperature water bath, and centrifuged for 15 minutes at 25 ° C 13,000rpm. Only insoluble portions of the dried fermented green tea extract were separated.
  • 150 g of the post-fermented tea sample was fractionated with acetone to remove catechin derivatives and caffeine as much as possible, and to obtain a soluble substance in which flavonoids were concentrated.
  • 40 g of the acetone solubles were first eluted using silica gel column chromatography with a mixture of chloroform: methanol in the order of 10: 1, 5: 1, 1: 1 (v / v) to obtain each fraction. .
  • trans-3-O-galloyl-3,3 ', 5,5', 7-pentahydroxyflavan Trans-3-O-galloyl-3,3 ', 5,5', 7- pentahydroxyflavan, C 22 H 18 O 10 , molecular weight 442.0900
  • the structure of the separated compound is shown below.
  • the trans-3-O-galloyl-3,3 ', 5,5', 7-pentahydroxyflavane was diluted to 0.2% concentration as a test substance, and 5% glycerin was used as a positive control. Used.
  • the skin moisture content of the test substance at the beginning, after 2 days, after 7 days, and after 11 days was measured with a coronometer (Corneometer CM825 (Courage + Khazaka electronic GmbH, Germany)) according to the following method.
  • the measuring principle of the conniometer is to measure the moisture level by measuring the amount of moisture by measuring the amount of water ions by using an electrical method and measuring the amount of moisture present in the skin epidermis.
  • a probe of a conniometer was placed on the skin area to be measured.
  • the electrical conductivity of the skin is quantified and displayed on the screen through a sensor, and the average value is obtained by measuring three times at each site repeatedly. The results are shown in Table 1 below.
  • trans-3-O-galloyl-3,3 ', 5,5', 7-pentahydroxyflavane when trans-3-O-galloyl-3,3 ', 5,5', 7-pentahydroxyflavane is applied to the skin, the skin moisture content tends to increase statistically significantly. (paired T-test, p ⁇ 0.01) and skin moisture was maintained 11 days after application. Therefore, the composition containing trans-3-O-galloyl-3,3 ', 5,5', 7-pentahydroxyflavane according to the present specification effectively preserves the moisture of the skin after application and has excellent skin moisturizing power. And it was found.
  • a soft capsule sheet was prepared at a ratio of 66 parts by weight of gelatin, 24 parts by weight of glycerine, and 10 parts by weight of sorbitol solution and filled with the filler to prepare a soft capsule.
  • trans-3-O-galloyl-3,3 ', 5,5', 7-pentahydroxyflavane 3mg, lactose 440mg, corn starch 450mg and magnesium stearate 2mg according to an embodiment of the present specification to soften
  • capsule fill solution prepared.
  • the soft capsule sheet was prepared as described above and the filling liquid was filled to prepare a soft capsule.
  • the sugar ester sugar ester 8 mg was added.
  • the composition was compressed into tablets in a conventional manner.
  • trans-3-O-galloyl-3,3 ', 5,5', 7-pentahydroxyflavane 3 mg vitamin E 15 mg, vitamin C 15 mg, galactooligosaccharide 259 mg, lactose 60 mg, Maltose 140 mg was mixed and granulated using a fluidized bed dryer, and then 8 mg of sugar ester was added. The composition was compressed into tablets in a conventional manner.
  • 400 ml of purified water was added thereto, and each bottle was filled with 200 ml. After filling the bottle sterilized for 4 to 5 seconds at 30 °C to prepare a drink.
  • vitamin E 9mg, vitamin C 9mg, 250mg anhydrous glucose and 550mg of starch according to the second specification of the present specification were mixed, molded into granules using a fluidized bed granulator, and then filled into a granule Was prepared.
  • trans-3-O-galloyl-3,3 ', 5,5', 7-pentahydroxyflavane 9 mg of vitamin E, 9 mg of vitamin C, 250 mg of anhydrous glucose, and 550 mg of starch were used.
  • the granules were prepared by mixing, molding into granules using a fluidized bed granulator, and filling into fabrics.
  • Injectables were prepared by conventional methods according to the compositions set forth in Table 2 below.
  • Vitamin A Acetate 70 ⁇ g Vitamin E 1.0 mg Vitamin B1 0.13 mg Vitamin B2 0.15 mg Vitamin B6 0.5 mg Vitamin B12 0.2 ⁇ g Vitamin c 10 mg Biotin 10 ⁇ g Nicotinic acid amide 1.7 mg Folic acid 50 ⁇ g Calcium Pantothenate 0.5 mg Mineral mixture Ferrous sulfate 1.75 mg Zinc oxide 0.82 mg Magnesium carbonate 25.3 mg Potassium phosphate monobasic 15 mg Dicalcium Phosphate 55 mg Potassium citrate 90 mg Calcium carbonate 100 mg Magnesium chloride 24.8 mg
  • composition ratio of the vitamin and mineral mixture is a composition that is relatively suitable for health foods as an example, the composition ratio may be arbitrarily modified, and the above ingredients are mixed according to a conventional health food manufacturing method, and then the conventional method. According to the health food composition can be used.
  • the remaining amount of purified water was added to a total volume of 900 ml, and the above ingredients were mixed according to a conventional healthy beverage manufacturing method, and then stirred and heated at 85 ° C. for about 1 hour, and then the resulting solution was filtered. Obtained in a sterilized 2 liter container, sterilized sealed, and then refrigerated to prepare a healthy beverage.
  • 3% by weight of the after-fermented tea acetone fraction according to Example 2 1.00% by weight of L-ascorbic acid-2-magnesium phosphate, 1.00% by weight of water-soluble collagen (1% aqueous solution), 0.10% by weight of sodium citrate, 0.05% by weight of citric acid Soft liquor (skin lotion) was prepared using 0.20 wt% licorice extract, 3.00 wt% 1,3-butylene glycol, and the remaining amount of purified water.
  • trans-3-O-galloyl-3,3 ', 5,5', 7-pentahydroxyflavane of the Example in place of the post-fermented tea acetone fraction 0.1% by weight to prepare a flexible cosmetic water.
  • Post-fermented tea acetone fraction according to Example 2 3.00% by weight, polyethylene glycol monostearate 2.00% by weight, self-emulsifying glycerin monostearate 5.00% by weight, propylene glycol 4.00% by weight, squalene 6.00% by weight, tri2-ethylhexane
  • a creamy formulation was prepared using 6.00% by weight of glyceryl, 1.00% by weight of sphingolipids, 7.00% by weight of 1,3-butylene glycol, 5.00% by weight of beeswax, and the remaining amount of purified water.
  • a cream formulation was prepared using 0.1 wt% of the trans-3-O-galloyl-3,3 ', 5,5', 7-pentahydroxyflavane of the example instead of the post-fermented tea acetone fraction.
  • the pack was prepared using 0.1 wt% of the trans-3-O-galloyl-3,3 ', 5,5', 7-pentahydroxyflavane of the Example instead of the post-fermented tea acetone fraction.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Botany (AREA)
  • Birds (AREA)
  • Polymers & Plastics (AREA)
  • Nutrition Science (AREA)
  • Biotechnology (AREA)
  • Dermatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • General Preparation And Processing Of Foods (AREA)
  • Cosmetics (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Dans un aspect, l'invention concerne une composition hydratante contenant un extrait de cétone de thé post-fermenté comme principe actif et, dans un autre aspect, une composition hydratante contenant du 3-O-galloyl-3,3',5,5',7-pentahydroxyflavane isolé à partir de l'extrait de cétone de thé post-fermenté, ou un isomère, un sel acceptable, un promédicament, un hydrate ou un solvate de celui-ci, comme principe actif. Ainsi, la présente invention devrait trouver des applications efficaces dans divers domaines liés à l'hydratation de la peau et analogue.
PCT/KR2017/007294 2016-07-20 2017-07-07 Composition hydratante contenant du 3-o-galloyl-3,3',5,5',7-pentahydroxyflavane WO2018016783A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2018526252A JP7030692B2 (ja) 2016-07-20 2017-07-07 ３－ｏ－ガロイル－３，３’，５，５’，７－ペンタヒドロキシフラボンを含む保湿用組成物
CN201780013667.7A CN108697143B (zh) 2016-07-20 2017-07-07 包含3-o-棓酰-3,3’,5,5’,7-五羟基黄烷的保湿用组合物
HK18113766.5A HK1254516A1 (zh) 2016-07-20 2018-10-29 包含3-o-棓酰-3，3'，5，5'，7-五羥基黃烷的保濕用組合物

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020160092229A KR102635190B1 (ko) 2016-07-20 2016-07-20 3-O-갈로일-3,3',5,5',7-펜타하이드록시플라반(3-O-galloyl-3,3',5,5',7- pentahydroxyflavan)을 포함하는 보습용 조성물
KR10-2016-0092229 2016-07-20

Publications (1)

Publication Number Publication Date
WO2018016783A1 true WO2018016783A1 (fr) 2018-01-25

Family

ID=60993153

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2017/007294 WO2018016783A1 (fr) 2016-07-20 2017-07-07 Composition hydratante contenant du 3-o-galloyl-3,3',5,5',7-pentahydroxyflavane

Country Status (5)

Country Link
JP (1) JP7030692B2 (fr)
KR (1) KR102635190B1 (fr)
CN (1) CN108697143B (fr)
HK (1) HK1254516A1 (fr)
WO (1) WO2018016783A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116162078A (zh) * 2022-12-27 2023-05-26 佛山病原微生物研究院 一种表没食子儿茶素没食子酸酯类化合物及其制备方法和应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20120021709A (ko) * 2010-08-13 2012-03-09 (주)아모레퍼시픽 플라보노이드 유도체를 함유하는 화장료 조성물
KR101222677B1 (ko) * 2010-07-30 2013-01-22 주식회사 비티씨 녹차 가수분해물을 유효성분으로 포함하는 항산화, 피부미백, 항노화용 조성물
WO2015053460A1 (fr) * 2013-10-11 2015-04-16 주식회사 아미코스메틱 Composition cosmétique contenant un liquide de baies de ginseng à fermentation de pleurotus ferulae
US9061023B2 (en) * 2007-10-26 2015-06-23 Csir Management and treatment of benign prostatic hyperplasia
WO2016093515A1 (fr) * 2014-12-09 2016-06-16 (주)아모레퍼시픽 Composition pour activer un gène de longévité

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0415181D0 (en) * 2004-07-06 2004-08-11 School Of Pharmacy The Univers Compounds for use in the treatment of infection
KR100975199B1 (ko) 2007-11-30 2010-08-10 (주)아모레퍼시픽 발효녹차의 제조방법 및 제조된 발효녹차

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9061023B2 (en) * 2007-10-26 2015-06-23 Csir Management and treatment of benign prostatic hyperplasia
KR101222677B1 (ko) * 2010-07-30 2013-01-22 주식회사 비티씨 녹차 가수분해물을 유효성분으로 포함하는 항산화, 피부미백, 항노화용 조성물
KR20120021709A (ko) * 2010-08-13 2012-03-09 (주)아모레퍼시픽 플라보노이드 유도체를 함유하는 화장료 조성물
WO2015053460A1 (fr) * 2013-10-11 2015-04-16 주식회사 아미코스메틱 Composition cosmétique contenant un liquide de baies de ginseng à fermentation de pleurotus ferulae
WO2016093515A1 (fr) * 2014-12-09 2016-06-16 (주)아모레퍼시픽 Composition pour activer un gène de longévité

Also Published As

Publication number Publication date
HK1254516A1 (zh) 2019-07-19
CN108697143B (zh) 2023-09-12
JP2019520786A (ja) 2019-07-25
CN108697143A (zh) 2018-10-23
JP7030692B2 (ja) 2022-03-07
KR20180010084A (ko) 2018-01-30
KR102635190B1 (ko) 2024-02-13

Similar Documents

Publication Publication Date Title
US9682029B2 (en) Ceramide production enhancer and moisturizer
WO2022177215A1 (fr) Procédé pour favoriser l'activité antioxydante de feuilles de thé pourpre
WO2016056781A1 (fr) Composition pour prévenir la chute des cheveux ou stimuler la pousse des cheveux comprenant un extrait d'artemisia umbelliformis
WO2018230906A1 (fr) Composition de blanchiment contenant un nouveau composé à base de quercétine
WO2018016783A1 (fr) Composition hydratante contenant du 3-o-galloyl-3,3',5,5',7-pentahydroxyflavane
WO2016056780A1 (fr) Composition pour prévenir la chute des cheveux ou stimuler la pousse des cheveux comprenant un extrait de scutellaria alpina
WO2018230909A1 (fr) Composition anti-inflammatoire comprenant un nouveau composé à base de kaempférol dérivé de thé post-fermenté
WO2016117762A1 (fr) Composition contenant un extrait de groseille à maquereau ou du glutathion
JP2000026228A (ja) コラゲナーゼ抑制剤、保湿剤並びにそれらを含む化粧料及び食品
WO2018034424A1 (fr) Composition antioxydante ou antivieillissement comprenant du 3-o-galloyl-3,3',5,5',7-pentahydroxyflavane
WO2018230910A1 (fr) Composition de blanchiment comprenant un nouveau composé à base de kaempférol dérivé de thé post-fermenté
WO2018230908A1 (fr) Composition anti-inflammatoire comprenant un nouveau composé à base de quercétine
WO2023149791A1 (fr) Composition à base d'extrait de phaseolus angularis wight en tant que principe actif pour la prévention et le traitement d'un oedème inflammatoire
WO2023058993A1 (fr) Composition pour l'anti-vieillissement et l'amélioration de la peau, comprenant un complexe constitué d'extrait de myrabolan emblique et d'extrait de germe d'orge (complexe ib) en tant que principe actif
JP2011231056A (ja) セラミド産生促進剤及び保湿剤
WO2020096348A1 (fr) Composition cosmétique contenant de la theasinensine a
JPH11335230A (ja) 皮膚外用剤
WO2023149785A1 (fr) Composition pour la prévention et le traitement d'un œdème inflammatoire, comprenant un extrait de lysimachia christinae hance comme principe actif
WO2015152552A1 (fr) Composition comprenant un extrait d'essence d'absinthe alpine
WO2018194375A1 (fr) Composition de prévention ou de traitement de la dermatite atopique, contenant un extrait de daphniphyllum sp. comme principe actif
WO2018016826A1 (fr) Composition contenant du 3-o-galloyl-3,3',5,5',7-pentahydroxyflavane pour améliorer la fonction cognitive
KR20210115315A (ko) 갈라세토페논을 포함하는 피부 미백용 조성물
WO2019059484A1 (fr) Composition permettant de prévenir la chute des cheveux ou de favoriser la pousse des cheveux, contenant un extrait de feuilles de carpinus tschonoskii
JP2012167022A (ja) セラミド産生促進剤、保湿剤及び皮膚外用剤
JP2012167023A (ja) セラミド産生促進剤、保湿剤及び皮膚外用剤

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref document number: 2018526252

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 201780013667.7

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17831256

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 17831256

Country of ref document: EP

Kind code of ref document: A1